Search
Vanda Pharmaceuticals Inc
VNDAAdd to Watchlist
5.100USD
-0.080-1.54%
Close 07-31 16:00（ET）Quotes delayed by 15 min
306.69MMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-07-31The current earnings forecast score of Vanda Pharmaceuticals Inc is 7.50, ranking 286 out of 385 in the Biotechnology & Medical Research industry. The average price target is 11.00, with a high of 20.00 and a low of 5.00.
Analyst Rating
Based on
4
analysts
Buy
Current Rating
14.125
Target Price
+176.96%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
496
Total
6
Median
7
Average
Company name
Ratings
Analysts
Vanda Pharmaceuticals Inc
VNDA
4
Beigene Ltd
ONC
28
Ionis Pharmaceuticals Inc
IONS
27
argenx SE
ARGX
26
Kymera Therapeutics Inc
KYMR
24
Insmed Inc
INSM
23
1
2
3
...
99
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Vanda Pharmaceuticals Inc's expected revenue for the next quarter?
Vanda Pharmaceuticals Inc's expected revenue is 61.92M.
What is Vanda Pharmaceuticals Inc's price target?
Analysts forecast that Vanda Pharmaceuticals Inc's price target is USD 11.00, with the highest forecast at USD 20.00 and the lowest forecast at USD 5.00.
How have Vanda Pharmaceuticals IncVNDA's recent earnings per share performed?
The market expectation was USD -0.82, while Vanda Pharmaceuticals IncVNDA's earnings per share (EPS) for the previous quarter was USD -2.39. EPS for the next quarter is expected at USD -0.59.
What is the analyst rating for Vanda Pharmaceuticals Inc?
Based on the ratings of Vanda Pharmaceuticals Inc's stock from 4 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.